- 7-Year Old Singer/Songwriter Kyra Pesebre Releases "I Love You, Dad" In Time For Father's Day - 452
- Waterside Productions Announces Said E. Dawlabani's New Book "The Light of Ishtar"
- Paul Sinacore Casting Shines Spotlight On "Friends: The Reunion" as Diversity Backlash Continues
Until now, therapeutic development for Alzheimer's disease has been almost uniformly unsuccessful, with over 400 failed clinical trials. The few "successes" (e.g., memantine) have not offered sustained improvement. For example, the recent claim of a positive trial for the drug candidate donanemab did not show cognitive improvement, nor even stabilization of dementia, but merely reduced the rate of progression by about one-third. Arguably, the greatest failure of medical treatments to date is in neurodegenerative diseases like Alzheimer's and Lou Gehrig's disease; about 45 million Americans are projected to die from Alzheimer's if effective treatment and prevention are not developed.
Posted in medRxiv on May 11th, the study, entitled Precision Medicine Approach to Alzheimer's Disease: Successful Proof-of-Concept Trial, used deeper dives into each patient's genetics and biomarkers in order to derive the optimal personalized, precision medicine protocol for each. The study was led by three integrative physicians—Drs. Kat Toups, Ann Hathaway, and Deborah Gordon—along with Dr. Dale Bredesen, a professor at UCLA.
More on The Californer
- Edison International Declares Q2 Dividends
- San Jose: FLASH REPORT #165 - COVID-19 Response and Recovery
- San Jose Mayor, City Council Unanimously Approve Acting City Manager for 10th Largest City in the Nation
- Confluent Announces Pricing of Initial Public Offering
- Cryptsoft's KMIP technology strengthens security in Networked Energy Services' Advanced Metering Infrastructure solutions
Their proof-of-concept trial included 25 participants, aged 50 to 76, all with MCI (pre-Alzheimer's) or early-stage dementia. Each patient was assessed for multiple potential contributors — inflammation, insulin resistance, nutrient and hormonal deficiencies, specific pathogens, toxicants, and biotoxins, as well as genetics— then treated with a personalized protocol that was continued for nine months. This is the same approach used by Apollo Health, which has developed software and programs to optimize the precision medicine protocol for cognitive decline. Addressing the presumptive root causes of the cognitive decline with this type of functional medicine approach has previously led to publications of anecdotal "case study" improvements, including Reversal of Cognitive Decline: 100 patients, but this is the first prospective clinical trial.
Cognitive testing revealed that among the study participants, 21 improved (84%), one showed no change (4%), and three declined (12%). Cognitive assessments included MoCA (Montreal Cognitive Assessment), CNS Vital Signs (an on-line, quantitative, multi-domain neuropsychological battery), Brain HQ (computerized brain training and assessment), AQ-21 (Alzheimer's Caregiver Assessment Questionnaire), and AQ-20, a caregiver measurement-of-change rating scale. MRI brain imaging complemented the cognitive testing and showed that the brain shrinkage that typically occurs with MCI and dementia was prevented.
More on The Californer
- SOS Hydration Partners With Original 'Shark' Kevin Harrington
- San Francisco: Mayor Breed Announces Historic Relaunch of The City's LGBTQI+ Advisory Committee on Pride Week
- SkyWest Airlines and SJVC Relaunch Apprenticeship Program
- Mayor London Breed Celebrates Completion of San Francisco's New Seismically Safe Emergency Medical Services Station No. 49, Home of The City's Ambulance Fleet
- The Power of Three: Helios Bioelectronics, GattaCo, and iAssay Unite to Clobber Infectious Disease
These strongly positive results support the view that identifying and treating the contributors to cognitive decline for each patient, with a personalized protocol, represents an effective treatment approach for patients with MCI or early dementia. The report concluded that a larger, randomized controlled trial is warranted, and this follow-up study is already in the works. The results reported by the group offer genuine hope to the millions of people with dementia or mild cognitive impairment, as well as those at risk due to family histories of dementia.
Co-authors included Kat Toups, M.D.; Ann Hathaway, M.D.; Deborah Gordon, M.D.; Cyrus Raji, M.D.; Sharon Hausman-Cohen, M.D.; Henrianna Chung; Alan Boyd; Benjamin Hill, Ph.D.; Mouna Attarha, Ph.D.; Won Jong Chwa; Michael Jarrett, Ph.D; and Dale Bredesen, M.D. This study was supported with funding by the Four Winds Foundation; performed in collaboration with QuesGen Systems, Inc. CRO. Dr. Bredesen is a consultant for Apollo Health, which was not involved in the funding, planning, execution, analysis, or publication of the trial.
SOURCE Apollo Health
Filed Under: Business
Latest on The Californer
- Hims & Hers Expands Hair Growth Offerings with Launch of Minoxidil 5% Foam
- Gamma Zeta Boulé Foundation Raises $190,000, Awards $83,000 in Scholarships to Eight Graduating Senior L.A.M.P. Mentor Program Mentees and Recognizes Three L.A.M.P. Mentees Selected as Boulé Scholars
- AdsWizz New Audio Attribution Solution Delivers Positive Results for Advertisers
- Cloud Gaming Market Size To Expand At 48.2% CAGR By 2027, Owing To Rising Investments In 5G Technology & Admittance To Several Games On Cloud At Reasonable Prices | Million Insights
- Infogain Recognized as 2nd Fastest Growing Company in Everest Group Engineering Services Top 50™ 2021
- thredUP Releases Its Ninth Annual Resale Report with First-Ever Impact Section
- Lamorinda Realtor Judy Sin Brokers Difficult Deal On Home With 2 Months Of Renovations Left
- As Mobile Usage Skyrockets, Nearly Half of Consumers Do Not Protect Personal Data
- California: Governor Newsom Declares State of Emergency for Madera and Mariposa Counties Due to January Wind Event
- Sintilimab in Combination with Chemotherapy Meets Overall Survival Primary Endpoint in the Global Phase 3 ORIENT-15 Study for the First-Line Treatment of Esophageal Squamous Cell Carcinoma
- Second Sight Medical Products Announces Pricing of Public Offering
- Maleimide Activated OVA-Peptide Conjugation Kit
- Meet Dr. Karen Tran-Harding - Creator, Host & Producer of MEDICAL HEROES
- San Francisco: Mayor London Breed and Supervisor Rafael Mandelman Introduce Legislation to Expand LGBTQ Data Collection for City Employees and Applicants
- The Law Offices of Frank R. Cruz Announces Investigation of MicroStrategy Incorporated (MSTR) on Behalf of Investors
- Innovaccer Partners With Perception Health to Power Smart Referral Management With Predictive Analytics
- Top Executive from Under Armour Joins CEO Coaching International®
- Innovative Tour of the Elkhorn Slough
- Surface Optics Awarded NAVAIR SBIR Grant to Develop Multispectral Imaging System for Detectio
- San Jose: : Fireworks 'Just Not Worth It' – Celebrate Safely this Fourth of July